| Literature DB >> 26199582 |
Nwozo Sarah Onyenibe1, Kasumu Titilayo Fowokemi1, Oyinloye Babatunji Emmanuel2.
Abstract
To evaluate the cholesterol lowering potential and protective ability of aqueous extract of Monodora myristica experimental hypercholesterolemic rats, a short-term study was conducted. Hypercholesterolemia was induced by administering cholesterol orally at a dose of 40 mg/kg/0.3 ml. Plant extracts 100 or 200 mg/kg body weight and Questran 0.26 g/kg were administered five times a week for eight weeks for amelioration. Hypolipidemic effects were evaluated by measuring total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) in the serum, while the protective ability was measured by the extent of lipid peroxidation (LPO) as well as enzymatic and non-enzymatic antioxidants levels in post mitochondrial fractions (PMF) of the hepatic and cardiac homogenates. Serum aminotransferases activities were also monitored. Results obtained shows that treatment with M. myristica elicited a significant reduction in serum TC, TG and LDL-C levels while there was concomitant increase in HDL-C of hypercholesterolemic rats. Elevations in serum aminotransferases activities and LPO level were reversed and a significant amelioration was noticed in enzymatic and non-enzymatic antioxidants status in the liver and heart of hypercholesterolemic rats. This study suggests that M. myristica possess cholesterol lowering potentials and protective ability in experimental hypercholesterolemia rat model.Entities:
Keywords: Cholesterol; Monodora myristica; antioxidant; hypercholesterolemia; hypolipidemic; rats
Year: 2015 PMID: 26199582 PMCID: PMC4502738
Source DB: PubMed Journal: Int J Biomed Sci ISSN: 1550-9702
Effect of Monodora myristica on body weights (g) of cholesterol fed rats
| Groups | Body weight (g) | Weight gained (g) Percentage increase | |
|---|---|---|---|
| Initial weight | Final weight | ||
|
| |||
|
| 124.00 ± 7.58 | 156.66 ± 7.70 | 26.33 |
|
| 131.00 ± 6.53 | 159.00 ± 3.74 | 21.37 |
|
| 126.00 ± 4.00 | 156.80 ± 6.00 | 24.44 |
|
| 138.00 ± 6.63 | 180.00 ± 4.19 | 30.43 |
|
| 135.00 ± 4.00 | 166.20 ± 4.00 | 23.11 |
|
| 140.00 ± 4.47 | 162. 00 ± 6.12 | 15.71 |
Values are mean ± standard deviation, (where n=6);
The mean is significant (P<0.05) when compared with control;
The mean is significant (P<0.05) when compared with standard drug only.
Effect of Monodora myristica on HDL-c, LDL-c, total cholesterol and triglyceride levels of cholesterol fed rats
| Groups | HDL-c (mg/dl) | LDL-c (mg/dl) | Total cholesterol (mg/dl) | Triglyceride (mg/dl) |
|---|---|---|---|---|
|
| ||||
|
| 1.24 ± 0.61 | 0.95 ± 0.05 | 58.01 ± 5.71 | 38.41 ± 1.53 |
|
| 1.46 ± 0.09 | 1.14 ± 0.39 | 104.15 ± 5.27 | 44.66 ± 1.18 |
|
| 1.27 ± 0.43 | 1.01 ± 0.13 | 100.36 ± 1.96 | 43.48 ±1.55 |
|
| 0.25 ± 0.08 | 1.39 ± 0.14 | 132.41 ± 10.50 | 58.05 ± 0.59 |
|
| 1.94 ± 0.07 | 1.27 ± 0.25 | 99.38 ± 1.59 | 40.93 ± 0.84 |
|
| 1.96 ± 0.07 | 1.08 ± 0.14 | 91.76 ± 0.85 | 35.89 ± 4.06 |
Values are mean ± standard deviation, (where n=6).
The mean is significant (P<0.05) when compared with control,
The mean is significant (P<0.05) when compared with standard drug only;
The mean is significant (P<0.05) when compared with cholesterol.
Effect of Monodora myristica on hepatic SOD, CAT, GSH and MDA levels of cholesterol fed rats
| Groups | SOD (μmol/min) | CAT (μmol/min) | GSH (μg/ml) | MDA (mg/dl) |
|---|---|---|---|---|
|
| ||||
|
| 83.33 ± 4.01 | 275.67 ± 6.17 | 118.17 ± 1.01 | 2.87 ± 0.44 |
|
| 70.56 ± 1.32 | 209.33 ± 7.68 | 117.83 ± 4.76 | 3.87 ± 0.49 |
|
| 76.68 ± 0.46 | 219.67 ± 3.18 | 114.50 ± 2.78 | 3.87 ± 0.49 |
|
| 68.04 ± 1.74 | 207.33 ± 4.06 | 88.333 ± 21.67 | 5.67 ± 0.73 |
|
| 78.82 ± 1.50 | 274.67 ± 15.68 | 114.52 ± 2.78 | 4.30 ± 3.79 |
|
| 80.30 ± 1.52 | 277.78 ± 2.99 | 118.17 ± 1.01 | 4.23 ± 1.15 |
Values are mean ± standard deviation, (where n=6).
The mean is significant (P<0.05) when compared with control;
The mean is significant (P<0.05) when compared with standard drug only;
The mean is significant (P<0.05) when compared with cholesterol.
Effect of Monodora myristica on cardiac SOD, CAT, GSH and MDA levels of cholesterol fed rats
| Groups | SOD (μmol/min) | CAT (μmol/min) | GSH (μg/ml) | MDA (mg/dl) |
|---|---|---|---|---|
|
| ||||
|
| 85.86 ± 4.04 | 160.19 ± 3.55 | 120.67 ± 1.17 | 1.53 ± 0.23 |
|
| 78.93 ± 1.49 | 152.49 ± 4.29 | 117.33 ± 0.83 | 3.93 ± 0.15 |
|
| 74.01 ± 1.96 | 208.62 ± 4.68 | 117.83 ± 0.85 | 4.33 ± 1.45 |
|
| 78.13 ± 4.00 | 129.54 ± 74.82 | 116.67 ± 0.44 | 6.33 ± 1.20 |
|
| 80.47 ± 1.35 | 212.92 ± 4.11 | 118.83 ± 2.85 | 3.37 ± 0.12 |
|
| 88.51 ± 1.32 | 221.85 ± 5.03 | 121.33 ± 1.67 | 2.10 ± 0.38 |
Values are mean ± standard deviation, (where n=6).
The mean is significant (P<0.05) when compared with control;
The mean is significant (P<0.05) when compared with standard drug only;
Effect of Monodora myristica on tissue protein levels, AST and ALT activities in cholesterol fed rats
| Groups | AST (U/l) | ALT (U/l) | Liver protein conc. (mg/dl) | Heart protein conc. (mg/dl) |
|---|---|---|---|---|
|
| ||||
|
| 24.77 ± 0.62 | 7.90 ± 0.27 | 10.33 ± 0.60 | 30.01 ± 1.26 |
|
| 15.83 ± 0.60 | 6.13 ± 0.62 | 13.00 ± 1.12 | 31.53 ± 0.98 |
|
| 20.78 ± 1.12 | 23.13 ± 0.75 | 16.73 ± 1.35 | 23.57 ± 0.97 |
|
| 108.40 ± 2.14 | 29.20 ± 0.73 | 14.20 ±1.50 | 24.83 ± 1.75 |
|
| 92.07 ± 0.66 | 6.35 ± 0.29 | 22.70 ± 1.30 | 22.70 ± 1.30 |
|
| 89.35 ± 0.55 | 6.35 ± 0.29 | 30.01 ± 1.26 | 29.87 ± 1.66 |
Values are mean ± standard deviation, (where n=6).
The mean is significant (P<0.05) when compared with control;
The mean is significant (P<0.05) when compared with standard drug only;
The mean is significant (P<0.05) when compared with cholesterol.
Figure 1Histological analysis of liver sections. Liver tissues were stained with H&E (× 400). A, Control: showing normal liver histology, no abnormalities was seen; B, Rats receiving Questran (standard drug) showing prominent sinusoid; C, Rats receiving standard drug and cholesterol showing mild kupffer cell proliferation with moderate hepatic vacoular degeneration; D, Rats receiving cholesterol only showing marked portal congestion and vacuolar degeneration of the hepatocytes; E, Rats receiving cholesterol and Monodora Myristica at 100 mg/b. wt. showing moderate hepatic vacoular degeneration; F, Rats receiving cholesterol and Monodora Myristica extract at 200 mg/b. wt. showing moderate hepatic vacoular degeneration.